HK1237293A1 - Medical and veterinary applications of light to therapeutic compounds - Google Patents

Abstract

Medical and veterinary applications of light to therapeutic compounds include a solution retainer adapted to retain a therapeutic solution against a tissue of a user; a fiber optic cable; a light source that connects with the fiber optic cable and provides a light of a predetermined wavelength to the fiber optic cable; and a light termination on the fiber optic cable that exposes the light to the therapeutic solution. A formulation includes an oxidizer; the therapeutic solution having an initial therapeutic effectiveness; and a light of a predetermined frequency that that undergoes a synergistic reaction with the oxidizer, thereby enhancing the initial therapeutic effectiveness of the solution.

Description

Human and veterinary applications of light for therapeutic compounds

Cross Reference to Related Applications

This application claims benefit of filing date of U.S. patent application No. 62/026,498 (P679-104) filed on 18/7/2014-the entire contents of which are incorporated herein by reference; the benefit of U.S. patent application No. 14/497,269 (P679-104A) filed 24/9/2014-the entire contents of which are hereby incorporated by reference into this application; this application claims the benefit of U.S. patent application No. 14/536,633 (P679-104B), filed on 9/11/2014-the entire contents of which are incorporated herein by reference; this application claims the benefit of U.S. patent application No. 14/583,580 (P679-104C) filed on 26.12.2014-the entire contents of which are hereby incorporated by reference into this application; U.S. patent application No. 14/630,513 (P679-104E) filed 24/2/2015 is also claimed-the entire contents of which are incorporated herein by reference; this application claims the benefit of U.S. patent application No. 14/638,902 (P679-104F) filed 3, 4, 2015-the entire contents of which are incorporated herein by reference; and this application claims the benefit of U.S. patent application No. 14/697,579 (P679-104D) filed on 27/4/2015-the entire contents of which are hereby incorporated by reference.

Background

The present invention relates generally to therapies involving the improvement of the effects of chemical agents by light, and more particularly to the human medical and veterinary applications of light to antibacterial and antineoplastic chemical agents, including antibacterial and antineoplastic solutions.

Pathogens that cause injury and disease are present in living tissues of humans and animals. Tumors or tumors, such as carcinomas, also cause damage to human and animal tissues.

It has been demonstrated that certain wavelengths of light act synergistically with certain drugs or targeted chemical agents, such as antibacterial and antitumor agents, to destroy or inhibit pathogen or tumor growth, thereby improving or "boosting" the effectiveness of such drugs or targeted chemical agents.

It is desirable to increase the exposure of certain antibacterial or antineoplastic agents or both to light so that a synergistic effect can be developed to destroy or inhibit the growth of pathogens or tumors.

Disclosure of Invention

In one aspect of the invention, an apparatus includes a solution holder, a fiber optic cable, a light source, and a light terminal, wherein the solution holder is adapted to contain a treatment solution for tissue of a user; the light source is connected with the fiber optic cable and provides light with a preset wavelength to the fiber optic cable; the light termination is located on the fiber optic cable and exposes the light to the treatment solution.

In another aspect of the invention, a formulation (also referred to as a formulation) comprises: a solution containing an oxidizing agent; a therapeutic solution having an initial therapeutic effect; and a predetermined frequency of light that synergistically reacts with the oxidizing agent to improve the initial therapeutic effect of the solution.

Drawings

FIG. 1 depicts an embodiment of a dental device according to the present invention;

FIG. 2 depicts an embodiment of a container according to the present invention;

fig. 3 depicts an embodiment of a bowl according to the present invention;

FIG. 4 depicts an embodiment of a full body suit according to the invention;

5A-5E depict embodiments of garments according to the present invention;

fig. 6 depicts an embodiment of a helmet according to the present invention;

FIG. 7 depicts an embodiment of a catheter according to the present invention;

FIG. 8 depicts an embodiment of a horse carpet according to the present invention; and

fig. 9A-9C depict embodiments of a mantle of an animal according to the present invention.

Detailed Description

Preferred embodiments and other embodiments which can be used in the industry and which include the best mode now known for carrying out the invention are described in detail herein with reference to the accompanying drawings. Further embodiments, features and advantages will become apparent from the ensuing description or may be learned without undue experimentation. The drawings are not necessarily drawn to scale unless otherwise indicated. The following description of the embodiments, even if wording "the invention" or what the embodiments do, should not be construed as having a limiting purpose, describes ways and processes of making and using the invention. The scope of coverage of this invention is as set forth in the claims. The order of steps set forth in the claims does not necessarily indicate that the steps must be performed in that order. The phrase "and/or" between two elements means that only the first element, only the second element, or both elements together.

Embodiments of the present invention generally provide devices and therapeutic solutions for applying light to therapeutic compounds for the purpose of human disease treatment and animal disease treatment.

Embodiments of the present invention generally provide a medicine having an improved effect by irradiating light of a predetermined frequency onto the medicine.

One embodiment of the present invention may provide a means to maintain the solution in contact with tissue, such as skin, teeth, or the skin of an animal, while the tissue and solution are simultaneously exposed to certain wavelengths of light. Such a device may have features that enhance the effect of the antimicrobial solution by using light of a certain wavelength. The antimicrobial, antineoplastic, or other therapeutic solution may or may not be activated by light at any given time. The treatment solution is "pressurized" by light when it is irradiated. This synergistic effect eliminates or reduces more pathogens than using the solution alone.

Various embodiments of the treatment solution may maintain an oxidizing agent, an antimicrobial agent, or an antineoplastic agent in contact with tissue, such as human or animal skin, while the tissue and solution are simultaneously exposed to certain wavelengths of light. Various embodiments may have components that enhance the effectiveness of antimicrobial, antiviral, and antitumor solutions by using certain wavelengths of light. When light is applied to the solution, the solution is "pressurized" by the light. This synergistic effect eliminates or reduces more germs or bumps than using the solution alone. This can be achieved in a variety of ways, including: light directly from a light source, or from a light combined with a dental tray or other disc or container, a mask, bandage, horse cover blanket or animal hood, or a device for applying an antibacterial or anti-tumor chemical for treatment.

There are pathogens in living tissue that cause injury or disease. By adding light radiation of a certain wavelength to a device that holds certain therapeutic agents close to tissue, a synergistic effect can be created to destroy or inhibit pathogens or tumor growth. For example, in the oral cavity, such devices may be disks designed to cover the teeth and gums. Such discs will emit light of certain wavelengths which, when combined with certain antimicrobial and/or antineoplastic solutions in the discs, will result in a synergistic antimicrobial and/or antineoplastic effect. The light may be generated, for example, by a Light Emitting Diode (LED) or a laser. The external light source may be connected to the fiber optic cable in a solution containing device having a fiber optic connection cable, which may further include a fiber optic connection joint or plug.

Various embodiments of the invention may form additional ways to treat disease. An antimicrobial or anti-tumor solution pressurized by light of certain wavelengths may result in the solution eliminating or reducing pathogens and/or tumor tissue by a higher percentage than if the solution were used alone. Various embodiments may create a synergistic effect between certain wavelengths of light and an antimicrobial and/or anti-tumor solution that, when applied to tissue, eliminates or reduces disease-causing microorganisms and/or tumor tissue.

Various embodiments of the invention may include solution containment devices or means that emit light at certain wavelengths into the solution. When this combination of light and solution is applied to tissue, a synergistic effect is created that reduces or eliminates disease-causing microorganisms and/or tumor tissue. The basic component is 1. The solution holding apparatus is 2. The light source is 3. With an antimicrobial solution or an anti-tumor solution or both.

Various embodiments may employ blue light or some other predetermined wavelength of light that is pressurized by exposure to light for a few seconds to a few minutes. Various embodiments may also include H2O2 solutions-such as gels-with a suitable 0.3mM concentration or any concentration of solution of, for example, an antibacterial, antiviral, or antitumor agent or compound.

In one embodiment, for safety, a "glow chart" may indicate that a 130 degree fahrenheit water exposure for 30 seconds is safe, but results in burns beyond. Water exposure of 120 degrees fahrenheit for up to 5 minutes may be safe. Hydrogen peroxide (H2O2) was able to kill 96% of pathogens in 20 seconds when exposed to 400-500nm wavelength light. This solution works best at 57 degrees celsius (134 degrees fahrenheit).

Various alternative embodiments may include a heating element that may heat the treatment solution to warm and further achieve pressurization. In various embodiments, an apparatus may comprise heating or cooling components, or both. In one embodiment, the antimicrobial solution may be preheated to a desired or optimal temperature prior to its exposure to the synergistic light, or used with or without a change in pH. For example, hydrogen peroxide may be exposed to 400-500nm light, preferably at 57 degrees Celsius (134 degrees Fahrenheit), for less than 20 seconds. Other chemicals may have different preferred temperatures and pH values.

Embodiments of the human medical and veterinary device may include an integrated or internal heating element disposed in the device adjacent to the light emitting cable. Embodiments of the integrated heating element may be positioned in only a portion of the device-for example at the bottom of a container, garment, or sleeve. The heating element may draw power from the same source as the light source, such as a battery or an external power source (wall power). Energy can be supplied to the heating element in the device via a fiber optic connection cable or via an energy connection cable, which runs alongside the connection cable.

Various alternative embodiments of the heating element may be spaced apart from the portion of the device containing the therapeutic solution. A separate heating element may heat the therapeutic solution to an optimal temperature before the solution is added to the device, such as by a heating pan or oven, or may be used to heat the antimicrobial and/or antineoplastic solution in place, such as by a soldering iron or wire.

Various embodiments of the device may include a fiber optic light cable that exposes the treatment solution to light of a certain wavelength, such as a purposefully selected wavelength or frequency of light from an LED or laser. The mantle may contain an antimicrobial solution. One embodiment may include multiple light terminations or other light emitting devices on the light emitting fiber optic cable. Each light terminal is spliced into a fiber optic cable to output some light at the end of the terminal to emit light into the treatment solution. The device can be adjustable so that terminals can be added or moved or the number and location of light terminals can be measured to accommodate a single user. The light ray terminations may be positioned within or on the mantle surface such that each light ray termination will be positioned within a predetermined location within the holder, such as a location adjacent to the tissue to be treated. The fiber optic cable may be opaque and the light emitting devices spaced along its length, or may be at least partially translucent so as to emit light along its length. The user may be a human or an animal.

In one embodiment, the fiber optic cable may be connected to the light source by a fiber optic connection cable. The connection cable may enter the holder or mantle and be optically connected with the fiber optic cable by a fiber optic connection joint so that the light source may be connected and disconnected after use. One embodiment of the joint may include a fiber optic connection cable mounted to a fiber optic cable. Another embodiment of the joint may include a socket that mates with a plug on a connection cable so that the light source may be connected and disconnected after use.

One embodiment may include a device having a light source and an antimicrobial and/or antineoplastic solution. Various embodiments may include various human and animal bodies or body part covers.

One embodiment of the invention may include a holder or shroud for applying a therapeutic solution to a human, horse or other animal. The holder may be connected to a light source. Various embodiments may include a plurality of fiber optic terminations. The holder may have a heating element.

Various embodiments of the holder may include: a dental tray containing an antibacterial, anti-tumor or other treatment solution for a user's teeth; a medical solution holder adapted to hold an antimicrobial or antineoplastic solution for tissue of a human user; a bucket or container; a bowl; sleeving the whole body; sleeves for arms; a glove with fingers; a stocking; toe caps; a helmet; a conduit; a medical or therapeutic solution holder adapted to hold an antimicrobial or antineoplastic solution for tissue of an animal; carpeting for horses or other animals; or a cover for a limb or body part of an animal.

Various embodiments may include a fiber optic cable wrapped around an inner surface of the device. The fiber optic cable may have light terminations spaced along the fiber optic cable within the device. One embodiment may include a heating element within the device. The heating element may comprise a heating wire extending within the device adjacent the fibre optic cable. The fiber optic cable may be connected to the light source by a connection cable. The connection interface or plug may connect or release an external light source from the device. The heating element may receive energy from the light sources through the same light source connection cable or through a single energy connection cable. The switch may allow the light source to be connected, the heating energy, or both to be turned on or off.

To use one embodiment, the therapist may apply the treatment solution to the interior of the device and then wear the device on a human or animal to receive treatment. The therapist may turn on the heater or the power source or both.

Various embodiments of the therapeutic solution may include an antibacterial, antiviral, antitumor compound in contact with human or animal skin. Such solutions may be in the form of liquids, gels, mixtures, creams or other suitable forms. The solution may or may not be heated by the device. Various embodiments may or may not include a compound to adjust the pH of the solution.

Various embodiments may include a light source that emits light at certain wavelengths, which may be 400-500 nM. Such a light source may be manual. The light source may be in contact with the treatment solution or may be held or placed within an effective distance. The combination of the antimicrobial and/or antitumor solution and light of a certain wavelength may form a synergistic effect, resulting in a reaction that is greater than the sum of the reactions of the components alone (synergistic effect). Various embodiments of this combination of certain wavelengths of light with an antimicrobial and/or anti-tumor solution may be used to treat acne, actinic keratosis, or any other skin or systemic condition or disorder.

Once applied, the antibacterial, antiviral, antitumor or other therapeutic chemical agent may be exposed to light of wavelengths that form a synergistic effect, improving the effectiveness of the therapeutic chemical agent. This synergistic effect results in a greater reduction of bacteria associated with pathogens or tumor-associated tumors than would be possible with treatment solutions alone or light alone.

In one embodiment, the chemical agent may be used without a reservoir. The chemical agent may be inserted directly into the body cavity and exposed to light through a fiber optic rod having a plurality of light emitting fibers. Various embodiments of the carrier or reservoir may be a solution itself or a gel. Such gels may be inserted into a body cavity through a catheter and exposed to a coordinated light through the same catheter or a different catheter. The delivery device may include, but is not limited to, a reservoir, a bandage, a gel, a solution, a head covering, an animal cover, a wrap, a sock, a stocking, a hat, a helmet, a composition, a suit, a tent, a probe, or a catheter.

Hydrogen peroxide (H2O2) can be either an oxidizing agent or a reducing agent. When H2O2 is used as the oxidant, oxygen is reduced to H2O. When H2O2 was used as the reducing agent, oxygen was oxidized to O2 and the generation of bubbles was seen. Various embodiments of the present invention may employ the formulated product of H2O2 and H2O2 as an oxidizing or reducing agent to provide an antibacterial, antitumor, and/or antiviral effect. The formulation or drug will include "oxidizing agent" (if it includes H2O 2).

Embodiments of the medicament include components that include certain wavelengths of light and chemical agents that inhibit, retard, and/or prevent microbial and/or bacterial and/or tumor growth, either alone or in combination with other means. The drug may be similar to an antibacterial and/or antiviral and/or antitumor chemical agent in terms of its chemical and functional profile in a living organism. The drug may have light as one of its components. It reliably produces in humans or other animals an effect similar to that of an antibacterial and/or antiviral and/or antitumor agent in a clinically prescribed dose. It is designated as a wavelength of light that controls at least one or more of the following chemicals: H2O2, lauric acid, dodecanoic acid, topical antibiotic, topical anesthetic, nicotinic acid, nicotinamide, antibacterial agents such as clindamycin phosphate, Methyl 7-chloro-6, 7, 8-trihydroxy-6- (1-Methyl-trans-4-propyl-L-2-carboxamide azalane) -1-thio-L-threo-alpha-D-lacto-octapyranoside 2- (dihydrogenphosphate) (Methyl 7-chloro-6, 7, 8-trideoxy-6- (1-Methyl-trans-4-propyl-L-2-pyrrolidinecarboxamide) -1-thio-L-thio-alpha-D-galactono-octopyranoside 2- (dihydrogenphosphate)), salicylic acid, nicotinic acid, nicotinamide, and dihydrogenphosphate, Sulfur, retinoids such as 6- [3- (1-adamantane) -4-methoxy-phenyl ] naphthalene-2-carboxylic acid, alpha hydroxy acids, retinoic acid, borax, caprylic acid, capric acid, myristic acid and additional chemicals useful in the method.

The pharmaceutical dosage form of the present invention may include certain wavelengths of light and mixtures of one or more of the following chemical agents: H2O2, lauric acid, dodecanoic acid, topical antibiotic, topical anesthetic, nicotinic acid, nicotinamide, antibacterial agents such as clindamycin phosphate, methyl 7-chloro-6, 7, 8-trihydroxy-6- (1-methyl-trans-4-propyl-L-2-carboxamide azalane) -1-thio-L-threo-alpha-D-lacto-octapyranoside 2- (dihydrogenphosphate), salicylic acid, sulfur, retinoids such as 6- [3- (1-adamantane) -4-methoxy-phenyl ] naphthalene-2-carboxylic acid, alpha hydroxy acids, retinoic acid, borax, caprylic acid, capric acid, myristic acid and additional chemical agents useful in the methods including pharmaceutically acceptable carriers.

Various embodiments of the targeted chemical agent may include a compound having one or more of an antimicrobial, a biocide, or an antimicrobial agent. Various embodiments of the antimicrobial agent may include chlorhexidine compounds. Various embodiments of the targeted chemical agent may include non-steroidal anti-inflammatory compounds, such as derivatives of indene. Various embodiments of the targeted chemical agent may include an iodine compound. Various embodiments of the targeting chemical agent may include tumor necrosis factor, or a component of a TNF family cytokine. Various embodiments of the targeting chemical agent may include a metal-e.g., silver (Ag) or a transition metal such as Cu or Fe. Various embodiments of the targeted chemical agent may include an enzyme. Various embodiments of the enzyme may include one or more of a protease, a pectinase, or an elastase. Various embodiments of the targeted chemical agent may include an anti-tumor agent. Various embodiments of the targeted chemical agent may include an antibiotic-such as ciprofloxacin. Various embodiments of the targeted chemical may include spasmolytics-such as methylene chloride (methylene chloride).

In one embodiment, the first reaction may include the combination of light of a certain wavelength, e.g., 400-500nm, with an oxidizing agent, such as hydrogen peroxide. The light plus oxidizing agent may be entirely self-treating. The second reaction may include the binding of light of a certain wavelength to the oxidizing agent and further to the targeted chemical agent where the synergistic reaction takes place. Various embodiments of the medicament may include oxidizing agents that have been modified with light and targeting chemical agents that have been modified with light in order to provide a medicament with a therapeutic effect that has been modified with light. The drug may be a solution that remains in contact with the user when light is applied from a light source, or a solution that may be modified with light prior to application. The light may comprise two frequencies of light applied simultaneously to the drug or solution, or may be applied in a manner that applies a first frequency of light followed by a successive application of a second frequency of light.

The selected targeting chemical agent may be used in combination with a surfactant, wetting agent, chelating agent, or beneficial component. The various embodiments of the medical drug can be used in the form of tablets, pills, capsules, gels, liquids, sprays, mixtures, creams or pastes. Various embodiments can be used at varying temperatures to adjust their efficacy.

Dental applianceFig. 1 depicts an embodiment of a dental device 10. The light emitting fiber optic cable 12 may expose the antimicrobial solution 14 to light of a certain wavelength, such as a purposefully selected wavelength or frequency of light from an LED or laser. The disk 16 may contain an antimicrobial solution 14. In one embodiment, a plurality of light terminations 18 or other light emitting devices may be included on the light emitting fiber optic cable 12. Each light terminal 18 is spliced into the fiber optic cable 12 to output light at the top of the terminal to emit light into the antimicrobial solution 14. The device can be adjustable so that it can be addedPlus or mobile terminals 18 or may measure the number and location of light terminals 18 to accommodate a single user. The light ray end terminals 18 may be positioned within the disk 16 such that each light ray end terminal 18 will be positioned between adjacent teeth or adjacent to the teeth of the user. The fiber optic cable may be opaque and the light emitting devices spaced along its length, or may be at least partially translucent so as to emit light along its length. In one embodiment, the fiber optic cable 12 may be connected to the light source 20 by a fiber optic connection cable 22. A connection cable 22 may enter the tray 16 and be optically connected with the fiber optic cable 12 by a fiber optic connection joint 24 so that the light source 20 may be connected and disconnected after use. One embodiment of the joint 24 may include an aperture in the wall of the tray 16 where the fiber optic connection cable 22 is mounted to the fiber optic cable 12. Another embodiment of the interface 24 may include a socket on the tray 16 that mates with a plug on the connection cable 22 so that the light source 20 may be connected and disconnected after use.

Container with a lidAs depicted in fig. 2, an embodiment of the medical device 30 may include a container 32, the container 32 having walls 34, a bottom 36, and a carrying handle 38. Various embodiments may include a fiber optic cable 40 wrapped around the inner surface of the wall 34. The light termination 42 may be located on the fiber optic cable 40 inside the container. The heating element 44 may be positioned around the bottom of the container 32. The fiber optic cable 40 may be connected to the light source 46 by a fiber optic connection cable 48.

Bowl-shaped componentAs depicted in fig. 3, an embodiment of the medical device 50 may include a bowl 52 having a fiber optic cable 54, the fiber optic cable 54 wrapped around an inner surface 56 of the bowl 52. The fiber optic cable 54 may have a light termination 58. Various embodiments may have a base 60, and the base 60 may contain a heating element 62. The fiber optic cable 54 may be connected to the light source 64 by a fiber optic connection cable 66. Light source 64 may include an on/off switch 68 or a timer control 69.

Whole body suitAs depicted in FIG. 4, embodiments of medical device 70 mayTo include a full body suit 72, the full body suit 72 has an integrated torso portion 74, sleeves 76, pants 78, foot portion 80, and hood 82, and a removable mitt 84 or mitt 86. Sleeves 76 may have cuffs 88 to wrap around the wrist of a user. The hood 82 may have a flexible portion 90 to grip the user's face. Embodiments may include, for example, an inlet tube 92 on one shoulder of torso portion 74 and an outlet tube 94 on the opposite shoulder of torso portion 74. Various embodiments may include fiber optic cables 96 spaced along the inner fabric of the suit 72. A light terminal 98 may be positioned on fiber optic cable 96 within encasement 72. The heating element may be embedded within the fabric of the suit 72. Either the fiber optic cable 96 or the heating element or both may be connected to the light source by a fiber optic connection cable.

Clothing articleFig. 5A, 5B, 5C, 5D, and 5E depict embodiments of medical devices that include a garment to carry a light modifying antimicrobial solution to a user wearing the garment. Fig. 5A depicts an embodiment of sleeve 122 of an arm. Fig. 5B depicts an embodiment of a glove 124. Figure 5C depicts an embodiment of toe sleeve 126. FIG. 5D depicts an embodiment of a stocking having a toe-covering portion 128 or no toe-covering portion 130. Fig. 5E depicts an embodiment of a pantyhose (foot stopping) 132 with a panty tape 134.

Helmet with a detachable headAs depicted in fig. 6, an embodiment of medical device 140 may include a helmet 142 having a fiber optic cable 144, fiber optic cable 144 wrapped around an inner surface 146 of helmet 142. Fiber optic cable 144 may have a light termination 148. Various embodiments may include a heating element 150, and the heating element 150 may include a wire located in the helmet liner. Fiber optic cable 144 may be connected to light source 152 by fiber optic connection cable 154.

Catheter tubeAs depicted in fig. 7, an embodiment of a medical device 160 may include a catheter 162 having a catheter tube 164, a distributor screen 166, and a fiber optic cable 168, the fiber optic cable 168 having one or more light terminations 170. The heating element 172 may be external to the conduit tube 164, anAnd a heated antimicrobial solution 174 may be provided through an input line 176. The light source 178 may be connected to a fiber optic cable 168 having a fiber optic connection joint 182 by a fiber optic connection cable 180.

Blanket with horse coverAs depicted in fig. 8, an embodiment of a complete horse cover blanket 200 may include a cover portion 202, a neck portion 204, and an upper leg portion 206. The blanket 200 may include a tape 208 to close the cover portion. The blanket 200 may be coated with an antimicrobial solution or gel on the inside thereof. Various embodiments may include a fiber optic cable 210, the fiber optic cable 210 being wrapped around an interior surface of the cover portion 202. Various embodiments may include a heating element 212, and the heating element 212 may include a heating wire inside the cover portion 202. Various embodiments may include a connection interface 214, the connection interface 214 connecting the fiber optic cable 210 to the light source 216. The light terminal 218 may be positioned on the fiber optic cable 210 inside the cover blanket 200. The light source 216 may have an on/off switch 200 or a timer control.

Animal coverAs depicted in the embodiment of fig. 9A, 9B, and 9C, the animal cover 230 may include a soft plastic sheet 232 and an attachment mechanism 234 at one end of the sheet 232. The shroud 230 may be wrapped around the neck of the animal and an attachment mechanism 234 on one end of the sheet may be attached to the other end of the sheet 232 to form a loop. Various embodiments may include soft fabric upholstery 46 at the top and bottom sides where the holster 230 contacts and rubs the animal or other object. The shroud 230 may be coated with an antimicrobial solution or gel on the inside. Various embodiments may include fiber optic cable 238, with fiber optic cable 238 wrapped around an inner surface of sheet 232. Various embodiments may include a heating element 240, and the heating element 240 may include a heating wire inside the mantle. Various embodiments may include a connection interface 228, the connection interface 228 connecting the fiber optic cable 238 to the light source 242. The light terminal 244 may be positioned on the fiber optic cable 238 inside the boot. The light source 230 may have an on/off switch 246 or a timer control.

Embodiments of a method of treating acne vulgaris ("acne") can comprise administering a therapeutically effective amount of a peroxide solution and light of a particular wavelength range, the specific wavelength range of light may be used in combination with one or more other antimicrobial agents or other chemical agents, the other antibacterial agents or other chemical agents may include local antibiotics, local anesthetics, niacin, niacinamide, antibacterial agents such as clindamycin phosphate, methyl 7-chloro-6, 7, 8-trihydroxy-6- (1-methyl-trans-4-propyl-L-2-carboxamide azalane) -1-thio-L-threo- α -D-lacto-octapyranoside 2- (dihydrogen phosphate). Various embodiments of the antimicrobial agent may include salicylic acid, sulfur, retinoids such as 6- [3- (1-adamantane) -4-methoxy-phenyl ] naphthalene-2-carboxylic acid, glycolic acid, retinoic acid, borax, and chemicals useful in the methods. Various embodiments of topical and systemic agents may be used as therapeutic chemicals in the embodiments of the present invention for treating acne, including hydrogen peroxide, urea peroxide, sulfur, retinoids such as 6- [3- (1-adamantane) -4-methoxy-phenyl ] naphthalene-2-carboxylic acid, glycolic acid, borax, resorcinol, salicylic acid, benzoyl peroxide, retinoic acid (tretinoin), and topical and systemic antibiotics. Embodiments comprising various peroxygenated compounds in combination with certain chemical agents can be effective in treating acne and have a synergistic effect in treating acne that is greater than would be expected by treatment of these individual agents by themselves. This synergistic effect has an even greater synergistic effect when exposed to certain wavelengths of light. The second chemical may be a treatment chemical or acne treatment chemical in that it contains ingredients that help to alleviate acne and is used for acne treatment or acne related therapy.

As an example, studies have shown that embodiments with hydrogen peroxide can kill 30% of bacteria exposed to hydrogen peroxide for 20 seconds. Light with a wavelength of 360nM-500nM can kill 3% of bacteria exposed to the light for 20 seconds. The combination of hydrogen peroxide and 360nM-500nM of light may have a synergistic effect of killing 96% of bacteria exposed to this combination for 20 seconds. The formulation of the solution used in embodiments of the invention may comprise hydrogen peroxide and/or urea peroxide and/or benzoyl peroxide and one or more selected from sulphur, retinoids such as 6- [3- (1-adamantane) -4-methoxy-phenyl ] naphthalene-2-carboxylic acid, glycolic acid, borax, resorcinol, salicylic acid, retinoic acid (tretinoin) and topical and systemic antibiotics.

In embodiments of the invention, topical solutions of hydrogen peroxide and/or carbamide peroxide and/or benzoyl peroxide, as well as other chemical agents believed to be effective, can be delivered in a variety of organic vehicles or carriers. Embodiments of the carrier may include a combination of ethanol and propylene glycol, wherein the active ingredient is present in a range of from about 0.001% to about 50% by volume of the carrier. The pH of the solution may be adjusted to minimize tissue sensitivity while the effect of the solution is unaffected. The temperature of the solution can be adjusted to optimize its effect.

For safety reasons and to optimize the effect of the solution, a "glow chart" may be provided or used. The graph may indicate that a 130 degree water exposure for 30 seconds is safe, but causes burns beyond that. Water exposure at 120 degrees for up to 5 minutes is safe. Solutions above normal body temperature will tend to open pores exposing bacteria to larger amounts of solution. Systemic antibacterial agents may be used as part of embodiments of such treatments in order to enhance their effectiveness. The solution may be exposed to light of a wavelength of 360nM-600nM or other wavelength that proves effective for a period of time ranging from 1 second to 1 minute. Embodiments may include solutions that may be warm, and light may form a synergistic effect unique to the invention. Such light may be used at varying distances from the solution in order to adjust its synergistic effect.

In additional embodiments, the topical solutions of the peroxy compound may include hydrogen peroxide and/or urea peroxide and/or benzoyl peroxide in a range of from about 0.001 to 50% by volume of the carrier in a variety of organic carriers. In various embodiments, the compounds may be contained in a variety of vehicles or carriers-including solutions, lotions, creams, gels, pastes, and ointments, as well as one or more of the following components: niacin or niacinamide capable of concentrations of from 0.001% to 30% by volume of the carrier; erythromycin, clindamycin phosphate, methyl 7-chloro-6, 7, 8-trihydroxy-6- (1-methyl-trans-4-propyl-L-2-carboxamide azalane) -1-thio-L-threo-alpha-D-lacto-octapyranoside 2- (dihydrogenphosphate) at a concentration of from 0.001% to about 30% by volume of the carrier. Various embodiments may have a concentration from 0.001 to 30% by volume; tetracycline hydrochloride at a concentration of from 0.001 to 30% by volume of the carrier; retinoids such as 6- [3- (1-adamantane) -4-methoxy-phenyl ] naphthalene-2-carboxylic acid; and other components that are believed to be effective in treating acne vulgaris. In various embodiments, these carriers may be beneficial in incorporating urea peroxide and may include ethanol and propylene glycol, surfactants such as lauryl ether and lauryl ester, and other carriers effective for the present invention. The carrier and active ingredients can be applied to the face or other affected area of the acne patient. The therapy can be administered at varying intervals, for example 1 to 4 times over a 24 hour period, so that open and closed comedones (blackheads and whiteheads) and inflammatory lesions are greatly reduced over a period of days to weeks, depending on the number of times the therapy is administered per day.

Embodiments of the present invention may provide an improved method for treating acne vulgaris involving the periodic use of an antimicrobial solution comprising an effective amount of a peroxide agent alone or in combination with one or more of a topical antibiotic, a topical anesthetic, niacin, niacinamide, an antimicrobial agent, salicylic acid, sulfur, a retinoid such as 6- [3- (1-adamantane) -4-methoxy-phenyl ] naphthalene-2-carboxylic acid, glycolic acid, retinoic acid (tretinoin), borax, and additional chemical agents beneficial in the method. This antimicrobial solution can be applied to patients with inflammatory disease, acne vulgaris. The antimicrobial solution can be adjusted to a temperature that is optimal for the treatment. The antimicrobial solution may be applied to the acne vulgaris areas and associated inflamed tissue. Once applied, the antimicrobial solution may be exposed to light of a wavelength that forms a synergistic effect, thereby improving the effectiveness of the antimicrobial solution. This synergistic effect may result in a more significant reduction of bacteria associated with acne vulgaris than by applying only an antimicrobial solution or only light.

Embodiments of the solution may contain a light activated pigment that fluoresces upon exposure to certain wavelengths of light applied in the therapy. Such pigments may indicate to the user that a synergistic effect has occurred.

The following specific examples help illustrate the invention, but the invention is not limited to the examples.

Example 1. In one embodiment, a 3% hydrogen peroxide solution in a gel is prepared. This solution was administered twice daily in topical application to the affected area of patients suffering from acne vulgaris. After application, the solution was exposed to light at a wavelength of 360nM-500nM for 20 seconds, resulting in a better synergistic effect than either light alone or solution alone. The entire affected area of the patient is exposed to this light at once by the LED device. The solution was then rinsed with clear water. After two weeks of treatment, the number of comedones in the patient, as well as the inflamed area resulting from acne vulgaris, will be significantly reduced. This synergistic effect between the solution and the light is unique to the present invention.

Example 2. In another embodiment, a solution comprising 3% hydrogen peroxide, 3% benzoyl peroxide and salicylic acid are combined in a carrier in a cream. The pH of this solution was buffered to 6. This cream was applied to the patient's area infected with acne vulgaris once a day. Once the cream was applied, it was exposed to a 10 watt manual lamp emitting light at wavelengths from 410nM to 500nM, thus creating a synergistic effect between the solution and the light, which resulted in a greater reduction of germs than when only light or only solution was used. The lamp may have a 15mm diameter end emitting such light. This particular size enables targeting of a smaller area of the patient. The exposure time of the light was one minute. This embodiment of the invention can be used to care for areas that were once infected with acne vulgaris. This synergistic relationship between light and solution is unique to the present invention.

Example 3. In yet another embodiment, the solution contains 15% urea peroxide, 2.5% clindamycin phosphate methyl 7-chloro-6, 7, 8-trihydroxy-6- (1-methyl-trans-4-propyl-L-2-carboxamide azalane) -1-thio-L-threo- α -D-lacto-octapyranoside 2- (dihydrogen phosphate). Various embodiments may include retinoic acid combined in a carrier in the form of a gel. This carrier solution was heated to 105 degrees fahrenheit. Once applied to the affected area, this warm solution helps open the pores of the patient. This solution was applied three times a day. The infected area was exposed to 410nM-500nM of light provided by a lamp that would expose an area 30 cm in diameter. The infected area and the solution were exposed to this particular wavelength of light for 30 seconds. The synergistic effect of light and a solution that may have been heated to warm is greater than the effect of light or solution alone. This synergistic effect between light and a solution that may have been heated to warm is unique to this invention.

Claims (15)

1. An apparatus, comprising:

a solution holder adapted to contain a therapeutic solution for a tissue of a user;

a fiber optic cable;

a light source connected to the fiber optic cable and providing light of a predetermined wavelength to the fiber optic cable; and

a light termination on the fiber optic cable and exposing light to the treatment solution.

2. The apparatus of claim 1, wherein:

the solution has an initial antimicrobial effect; and is

The light synergistically reacts with the therapeutic solution to improve the antimicrobial effect of the therapeutic solution.

3. The apparatus of claim 1, wherein:

the solution has an initial antimicrobial effect; and is

The light synergistically reacts with the therapeutic solution to improve the antimicrobial effect of the solution.

4. The device of claim 1, wherein the therapeutic solution is hydrogen peroxide and the light produces a synergistic reaction that improves the antimicrobial effect of the therapeutic solution.

5. The device of claim 1, wherein the treatment solution is an oxidizing agent in combination with a carrier, and the light produces a synergistic reaction that improves the effect of the treatment solution for treating acne vulgaris.

6. The device of claim 1, wherein the therapeutic solution is an anti-tumor agent and the light produces a synergistic response that improves the anti-cancer effect of the therapeutic solution.

7. The apparatus of claim 1, further comprising:

a heating element wrapped around an interior of the solution holder to heat the therapeutic agent to warm during application.

8. The apparatus of claim 1, further comprising:

an external light source providing light of a predetermined wavelength;

a fiber optic connection cable connecting the light source through the fiber optic cable; and

a receptacle on the solution holder that mates with a plug on the fiber optic connection cable so that the light source can be connected and disconnected.

9. The device of claim 1, wherein the solution holder comprises a dental tray containing the therapeutic solution in a cavity on a side of the tray;

the fiber optic cable is housed within the tray;

the tissue is a tooth of a user; and is

The tray is shaped to contain a light-irradiated treatment solution for the tooth;

and the device further comprises a plurality of light terminals on the fiber optic cable that emit light from the fiber optic cable into the treatment solution, the light terminals being positioned and in sufficient number so that there is at least one light terminal adjacent each of two opposing sides of each tooth.

10. The apparatus of claim 1, wherein the fiber optic cable includes a light emitting inner core and an outer protective layer covering only a portion of the light emitting inner core such that light is directed to the sides of the fiber optic cable.

11. The device of claim 1, wherein the solution holder comprises:

a full body suit for a human;

an input conduit that inputs the therapeutic solution as a mixture;

an area within the kit that circulates the composition to a user;

a discharge conduit that discharges the composition out of the kit; and is

Wherein the fiber optic cable is wrapped around an inner surface of the full body suit.

12. The device of claim 1, wherein the solution holder comprises a garment selected from the group consisting of:

a sleeve of an arm that covers and applies the therapeutic solution to an arm of a human user;

a fingered glove that covers and applies the therapeutic solution to a hand or a portion of a hand of a human user;

a stocking that covers and applies the therapeutic solution to a leg or a portion of a leg of a human user;

a toe sleeve covering one or more toes of a human user and applying the therapeutic solution to the one or more toes of the human user;

a helmet that covers a head of a human user and applies the therapeutic solution to the head of the human user; and

a blanket having cover portions shaped to cover the back, shoulders, sides and back of an animal, further having a strap with securing elements to releasably hold the blanket closed around the animal.

13. The device of claim 1, the solution holder comprising:

a catheter tube receiving the therapeutic solution at a first end of the catheter tube; and

a screen on the catheter proximate to a second catheter tube end opposite the first end to dispense the therapeutic solution into the user;

wherein the light termination is positioned on the fiber optic cable proximate the screen.

14. A formulated product comprising:

a solution comprising an oxidizing agent; a therapeutic solution having an initial therapeutic effect; and

a predetermined frequency of light that synergistically reacts with the oxidizing agent to improve the initial therapeutic effect of the solution.

15. The formulation of claim 14, wherein the therapeutic solution comprises a targeting chemical agent in combination with an oxidizing agent and the combined solution synergistically reacts with light to improve the antibacterial, antiviral, or antitumor effect of the therapeutic solution;

wherein the targeted chemical agent is selected from the group consisting of:

antibacterial, biocidal or disinfectant compounds;

an antibacterial compound comprising chlorhexidine;

non-steroidal anti-inflammatory compounds including derivatives of indene;

an iodine compound;

tumor necrosis factor;

a protease, pectinase or elastase compound;

ciprofloxacin;

spasmolytic; and

dichloromethane.